# GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

> **NCT02666287** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BAT/FF
- **DRUG:** BAT
- **DRUG:** FF
- **DRUG:** FF (MgSt)
- **DRUG:** FF/Vilanterol

## Key facts

- **NCT ID:** NCT02666287
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-27
- **Primary completion:** 2016-06-03
- **Final completion:** 2016-06-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02666287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02666287, "GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02666287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*